[go: up one dir, main page]

WO2021249563A1 - Dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation - Google Patents

Dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2021249563A1
WO2021249563A1 PCT/CN2021/099875 CN2021099875W WO2021249563A1 WO 2021249563 A1 WO2021249563 A1 WO 2021249563A1 CN 2021099875 W CN2021099875 W CN 2021099875W WO 2021249563 A1 WO2021249563 A1 WO 2021249563A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
cycloalkyl
compound
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/099875
Other languages
English (en)
Chinese (zh)
Inventor
吕彬华
崔大为
刘连军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zelgen Biopharmaceutical Co Ltd
Shanghai Zelgen Pharmatech Co Ltd
Original Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Shanghai Zelgen Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010534664.1A external-priority patent/CN113801113A/zh
Priority claimed from CN202011563650.9A external-priority patent/CN114671866A/zh
Application filed by Suzhou Zelgen Biopharmaceutical Co Ltd, Shanghai Zelgen Pharmatech Co Ltd filed Critical Suzhou Zelgen Biopharmaceutical Co Ltd
Publication of WO2021249563A1 publication Critical patent/WO2021249563A1/fr
Priority to PCT/CN2021/141360 priority Critical patent/WO2022135591A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the invention belongs to the field of medicine, and specifically relates to an aryl or heteroaryl pyridone or pyrimidinone derivative, and a preparation method and application thereof.
  • Lung cancer is one of the important causes of human cancer deaths.
  • lung cancer can be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • SCLC small cell lung cancer
  • NSCLC non-small cell lung cancer
  • the global NSCLC market in 2016 was approximately US$20.9 billion, of which the US market accounted for half, followed by Japan, Germany and China.
  • the non-small cell lung cancer market has maintained continuous growth, and the global market is expected to reach 54 billion U.S. dollars in 2023 (Nature, 2018; 553(7689):446-454).
  • chemotherapeutics mainly include gemcitabine, paclitaxel and platinum drugs, but these drugs generally have poor selectivity and high toxicity, which leads to relatively strong side effects.
  • molecular targeted drugs have gradually become research hotspots due to their high selectivity, relatively small side effects, and their obvious advantages such as precise treatment.
  • NSCLC molecular targeted drugs include EGFR inhibitors (such as afatinib, gefitinib, erlotinib, lapatinib, dacomitinib, icotinib, pirotinib, and nos) (Rociletinib, osimertinib, etc.), ALK inhibitors (such as ceritinib, alectinib, brigatinib, loratinib, okatinib, etc.), and VEGFR inhibitors ( Sorafenib, Regorafenib, Cabozantinib, Sunitinib, Donafenib, etc.).
  • EGFR inhibitors such as afatinib, gefitinib, erlotinib, lapatinib, dacomitinib, icotinib, pirotinib, and nos
  • EGFR inhibitors such as afatinib, gefitin
  • KRAS mutations are frequently detected, accounting for about 32% of all oncogene mutations.
  • KRAS G12C mutation accounts for 44% of all oncogene mutations in NSCLC. So far, no drugs targeting the KRAS G12C mutation have been approved on the market.
  • KRAS G12C target protein is pathologically related to a variety of diseases
  • KRAS G12C inhibitors for clinical treatment.
  • Highly selective and active KRAS G12C inhibitors can treat cancers and other diseases caused by KRAS G12C mutations more effectively, and reduce the potential for off-target effects, so they have more urgent clinical needs.
  • the purpose of the present invention is to provide a new type of compound with selective inhibitory effect on KRAS G12C and/or better pharmacodynamic performance and its use.
  • the first aspect of the present invention provides a compound of formula (I), its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug:
  • a and B are the same or different, and are independently selected from the following group: CH, CR 5 or N;
  • X is selected from the following group: 4-14 membered saturated or unsaturated heterocyclic group, C 4 -C 14 cycloalkyl group, C 6 -C 14 aryl group or 5-14 membered heteroaryl group, wherein the heterocyclic group
  • the radical, cycloalkyl, aryl or heteroaryl group may be optionally substituted by one or more (such as 2, 3 or 4) R 8 ;
  • U, V, W and Q are the same or different, and are each independently selected from the following group: CH, CR 3 or N;
  • R 1 is selected from the following group: in, Represents double bond " ⁇ " or triple bond " ⁇ ";
  • R A is absent, or independently selected from the following group: hydrogen, deuterium, fluorine, cyano or C 1 -C 3 alkyl; each R B is independently selected from the following group: hydrogen, deuterium, cyano or C 1 -C 3 alkyl; wherein, the alkyl can be substituted by one or more (such as 2, 3 or 4) substituents selected from the following group: deuterium, halogen, cyano, amine, C 3 -C 7 Cycloalkyl, 4-7 membered heterocyclyl, NHR 9 or NR 9 R 10 ; R 9 and R 10 are each independently a C 1 -C 3 alkyl group; or R 9 , R 10 and the N atom to which they are connected are formed together A substituted or unsubstituted 4-8 membered heterocyclic group;
  • p is an integer of 1 or 2;
  • R 3 is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 18 alkyl, deuterated C 1 -C 18 alkyl, halogenated C 1 -C 18 alkyl, C 3 -C 20 cycloalkyl, C 1 -C 18 alkoxy, deuterated C 1 -C 18 alkoxy, halogenated C 1 -C 18 alkoxy, halogen, nitro, hydroxyl, cyano, ester, amine Group, amide group, sulfonamide group, ureido group, 4-20 membered heterocyclic group, C 6 -C 14 aryl group, 5-14 membered heteroaryl group;
  • L is selected from the following group: bond, -C(O)-, C 1 -C 3 alkylene;
  • R 4 is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 18 alkyl, deuterated C 1 -C 18 alkyl, halogenated C 1 -C 18 alkyl, C 3 -C 20 cycloalkyl, C 1 -C 18 alkoxy, deuterated C 1 -C 18 alkoxy, halogenated C 1 -C 18 alkoxy, amino, hydroxyl, 4-20 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl;
  • R 5 is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 18 alkyl, deuterated C 1 -C 18 alkyl, halogenated C 1 -C 18 alkyl, C 3 -C 20 cycloalkyl, C 1 -C 18 alkoxy, deuterated C 1 -C 18 alkoxy, halogenated C 1 -C 18 alkoxy, halogen, nitro, hydroxyl, cyano, ester, amine Group, amide group, sulfonamide group, ureido group, 4-20 membered heterocyclic group, C 6 -C 14 aryl group, 5-14 membered heteroaryl group;
  • R 6 is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 18 alkyl, deuterated C 1 -C 18 alkyl, halogenated C 1 -C 18 alkyl, C 3 -C 20 cycloalkyl, C 1 -C 18 alkoxy, deuterated C 1 -C 18 alkoxy, halogenated C 1 -C 18 alkoxy, 4-20 membered heterocyclic group, C 6 -C 14 aryl Group, 5-14 membered heteroaryl group;
  • R 8 is independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 18 alkyl, deuterated C 1 -C 18 alkyl, halo C 1 -C 18 alkyl, C 3 -C 20 cycloalkyl, C 1 -C 18 alkoxy, deuterated C 1 -C 18 alkoxy, halogenated C 1 -C 18 alkoxy, amino, hydroxyl, 4-20 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl;
  • substitution refers to the substitution by one or more groups selected from the following group: hydrogen, deuterium, C 1 -C 18 alkyl, and deuterated C 1 -C 18 unless otherwise specified.
  • R 1 is selected from the following group: Among them, p is 2;
  • R 1 is selected from the following group: Among them, p is 2;
  • R 2 is not selected from:
  • L is not selected from bonds; and R 4 is not selected from:
  • the compound of the present invention does not include the following compounds:
  • the compound does not include the following compounds:
  • R 8 is each independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 6 alkyl, deuterated C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, deuterated C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkoxy, amino, hydroxyl, 4-8 membered heterocyclic group; the substitution refers to the substitution by one or more groups selected from the following group: hydrogen, deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, Sulfonamide group or urea group.
  • R 8 is each independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 18 alkyl, deuterated C 1 -C 18 alkyl, and halogenated C 1- C 18 alkyl; wherein, the substitution refers to substitution by a cyano group.
  • R A is independently selected from the following group: hydrogen, deuterium, fluorine, cyano or C 1 -C 3 alkyl
  • each R B is the same or different, and is independently selected from the following group: hydrogen, deuterium, cyano or C 1 -C 3 alkyl; wherein the alkyl can be substituted by one or more substituents selected from the group consisting of deuterium, halogen, cyano, amine, C 3 -C 7 cycloalkyl, 4- 7-membered heterocyclic group, NHR 9 or NR 9 R 10 ;
  • R 9 and R 10 are each independently a C 1 -C 3 alkyl group; or R 9 , R 10 and the N atom to which they are attached together form a substituted or unsubstituted 4 -8 membered heterocyclic group;
  • R 6 is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 6 alkyl, deuterated C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, deuterated C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkoxy, 4-8 membered heterocyclic group, C 6 -C 14 aromatic Group, 5-14 membered heteroaryl group;
  • substitution refers to the substitution by one or more groups selected from the following group: hydrogen, deuterium, C 1 -C 6 alkyl, and deuterated C 1 -C 6 unless otherwise specified.
  • R 3 is halogen
  • a and B are the same or different, and each independently is CH or N.
  • Q is N.
  • U is N.
  • V and W are each independently CR 3 , and R 3 is H or halogen.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (II-A) or (II-B):
  • R 1 , R 2 , R 4 , A, B, L, X, U, V, W, and Q are as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (III):
  • R 1 , R 2 , R 4 , X, L, U, V, W, and Q are as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (IV):
  • R 1 , R 2 , R 4 , R 8 , L, U, V, W, and Q are as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (V):
  • R 1 , R 2 , R 4 , R 8 , U, V, W, and Q are as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (VI):
  • R 1 , R 2 , R 4 , R 8 , U, V, and Q are as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs are characterized by Is that it has the structure represented by formula (VII):
  • R 1 , R 2 , R 4 , R 8 , V, and Q are as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (VIII):
  • R"' is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl, wherein the substitution refers to being selected from the following group Substitution of one or more groups: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4- C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl;
  • q is selected from: 1, 2, 3 or 4;
  • R 1 , R 4 , R 8 , R', V, and Q are as described above.
  • R 8 can be 1, 2, 3, or 4, or two adjacent R 8 can form a C 3 -C 6 cycloalkyl group together with the C atom to which they are connected.
  • R 1 is selected from:
  • the compound has a structure represented by formula (VIII-A):
  • R"' are each independently selected from the following group of substituted or unsubstituted groups: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3- C 8 cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl, wherein the substitution means being selected from One or more group substitutions of the group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl;
  • q is selected from: 1, 2, 3 or 4;
  • R 1 , R 4 , R 8 , R', V, and Q are as described above.
  • R 8 is each independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 6 alkyl, deuterated C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, wherein the substitution refers to substitution by a cyano group.
  • each R 8 is independently a substituted or unsubstituted C 1 -C 3 alkyl group, wherein the substitution refers to substitution by a cyano group.
  • each R 8 is a methyl group.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (IX):
  • R 1 is selected from: Wherein, R A is selected from: H, D, halogen or cyano; R B and R B'are the same or different, each independently selected from: H, D, halogen, cyano, substituted or unsubstituted C 1 -C 3 Alkyl; wherein, the substitution refers to substitution by one or more groups selected from the following group: D, halogen, cyano, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, 4 -6 membered heterocyclic group or NR IV R V ; R IV and R V are the same or different, each independently selected from: H, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl or 4-6 membered Heterocyclic group; or R IV , R V and adjacent N are cyclized together to form a 4-6 membered heterocyclic group;
  • R 4 , R', V, Q, R"' and q are as described above.
  • R"' is selected from substituted or unsubstituted groups: C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 10 cycloalkenyl, 4- 8-membered heterocyclic group, C 6 -C 10 aryl group, 5-10 membered heteroaryl group, wherein the substitution refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, Hydroxyl group, cyano group, ester group, amino group, amide group, C 1 -C 6 alkyl group, C 3 -C 8 cycloalkyl group, 4-8 membered heterocyclic group.
  • R"' is selected from the following group of substituted or unsubstituted groups: C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 4 -C 6 cycloalkenyl, 4- 6-membered heterocyclic group, wherein the substitution refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • R"' is selected from the following group of substituted or unsubstituted groups: C 3 -C 8 cycloalkyl, 4-8 membered heterocyclic group, wherein the substitution refers to being selected from One or more group substitutions of the group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • R"' is selected from the following substituted or unsubstituted groups: ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl Amino, azetidinyl, azetidinyl, azetidinyl, oxiranyl, oxetanyl, oxetanyl, oxetanyl, oxetanyl, wherein, the substitution refers to substitution by one or more (such as 2, 3, 4) groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • q is 1.
  • R 2 is selected from:
  • R 2 is selected from the following group:
  • K is independently O, S, CH 2 or NH; e and f are each independently 0, 1 or 2, preferably H in the above groups can be optionally deuterated, halogen, nitro, hydroxyl, cyano , Ester group, amine group, amide group, C 1 -C 3 alkyl substitution.
  • Part of it is selected from the following group:
  • K is independently O, S, CH 2 or NH; e and f are each independently 0, 1 or 2, preferably H in the above groups can be optionally deuterated, halogen, nitro, hydroxyl, cyano , Ester group, amine group, amide group, C 1 -C 3 alkyl substitution.
  • the compound has a structure represented by formula (VIII-1) or (VIII-2):
  • Rx is selected from: F or Cl
  • Rm is selected from the following group of substituted or unsubstituted groups: amino group, C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group, 4-6 membered heterocyclic group, wherein the substitution refers to the selected Substituting one or more groups from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, 4-6 membered heterocyclic group;
  • Rn is selected from the following group of substituted or unsubstituted groups: amino, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, -OC 3 -C 6 cycloalkane Group, C 1 -C 6 alkyl C 3 -C 6 cycloalkyl, -OC 1 -C 6 alkyl C 3 -C 6 cycloalkyl, 4-6 membered heterocyclic group, wherein the substitution refers to Substituted by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl , C 3 -C 6 cycloalkyl, 4-6 membered heterocyclic group;
  • R 1 The definition of R 1 is as described above.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs have The structure shown in formula (X) or (XI):
  • Rm is selected from the following group of substituted or unsubstituted groups: amino group, C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group, 4-6 membered heterocyclic group, wherein the substitution refers to the selected Substitution from one or more (such as 2, 3, 4) groups from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl, C3 -C6 cycloalkyl, 4-6 membered heterocyclic group;
  • Rn is selected from the following group of substituted or unsubstituted groups: amino, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, -OC 3 -C 6 cycloalkane Group, C 1 -C 6 alkyl C 3 -C 6 cycloalkyl, -OC 1 -C 6 alkyl C 3 -C 6 cycloalkyl, 4-6 membered heterocyclic group, wherein the substitution refers to Substitution by one or more (such as 2, 3, 4) groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl , C 1 -C 3 haloalkyl, C 3 -C 6 cycloalkyl, 4-6 membered heterocyclic group;
  • Rx is selected from: F or Cl
  • R A is selected from: H, D, halo, preferably, R A is selected from: H or F.
  • R"' is as described above;
  • q' is selected from 0, 1, 2, or 3.
  • the compound has a structure represented by formula (XII) or (XIII):
  • R b , R c can independently represent hydrogen, deuterium, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, 4-8 membered heterocyclic group, 5-14 membered heteroaryl or C 6 -C 14 aromatic ring, or R b and R c and N atom Together they can form a 4-8 membered heterocyclic group;
  • R e can independently represent hydrogen, C1-C 6 alkyl, C 3 -C 8 cycloal
  • the compound has a structure represented by formula (XIV) or (XV):
  • Rn is selected from the following group of substituted or unsubstituted groups: ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylamino, Azetidinyl, azetidinyl, azetidinyl, oxiranyl, oxetanyl, oxolanyl, oxetanyl, of which,
  • the substitution refers to substitution by one or more (such as 2, 3, 4) groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • Rm is selected from the following group of substituted or unsubstituted groups: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclo Propylamino, azetidinyl, azetidinyl, azetidinyl, oxiranyl, oxetanyl, oxetanyl, oxetanyl , oxetanyl , wherein, the substitution refers to substitution by one or more (such as 2, 3, 4) groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide , C 1 -C 3 alkyl.
  • Rn is selected from the following group of substituted or unsubstituted groups: ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylamino, Azetidinyl, azetidinyl, azetidinyl, oxiranyl, oxetanyl, oxolanyl, oxetanyl, of which,
  • the substitution refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl;
  • Rm is selected from the following group of substituted or unsubstituted groups: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylamino, azetidine Alkyl, azepanyl, azetidine, oxiranyl, oxetanyl, oxolane, oxetanyl, wherein the substitution is Refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • R 4b , R 4c and R 4d are H.
  • Rx is selected from: F or Cl.
  • R A is selected from: H, D, halo, preferably, R A is selected from: H or F.
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs do not contain
  • the compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs are selected from the examples The compound shown in.
  • the second aspect of the present invention provides a method for preparing a compound of formula (I), its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, Including steps:
  • E is halogen, OH, OCOR 1 , OCO ( i Bu), etc.
  • E 1 is -BH 2 , -B(OH) 2 , -Sn(Bu) 3 , -ZnBr, etc.;
  • PG is an amino protecting group, and the protecting group is selected from the group consisting of Boc, Bn, Cbz or Fmoc;
  • Y and Z are leaving groups, and the leaving groups are selected from the group consisting of halogen or OTf;
  • the first base is selected from the group consisting of KHMDS, NaHMDS, LiHMDS, NaH, NaOMe, NaOEt or t BuONa;
  • the second base is selected from the group consisting of TEA, DIPEA, DMAP or N,N-dimethylaniline;
  • R 1 , R 2 , R 4 , L, A, B, X, U, V, W, and Q are as described in the first aspect.
  • the third aspect of the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising one or more of the compounds of formula (I) described in the first aspect, its stereoisomers, tautomers, and crystal forms , Pharmaceutically acceptable salts, hydrates, solvates or prodrugs; and pharmaceutically acceptable carriers.
  • the pharmaceutical composition further comprises a drug selected from the group consisting of PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemipilimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT1306, AK105, LZM 009 or biosimilars of the above drugs, etc.), PD-L1 inhibitors (such as duvacizumab, Atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F520, GR1405, MSB2311 or biological analogues of the above drugs Etc.), CD20 antibodies (such as rituximab, obin utuzumab, ofatumumab,
  • MEK inhibitors e.g. Smeltinib (AZD6244), Trametinib (GSK11 20212), PD0325901, U0126, Pimasertib (AS-703026), PD184352 (CI-1040), etc.
  • mTOR inhibitors such as Vistusertib, etc.
  • SHP2 inhibitors such as RMC-4630, JAB-30
  • a method for preparing a pharmaceutical composition which includes the steps of combining a pharmaceutically acceptable carrier with the compound of formula (I), stereoisomers, and tautomers described in the first aspect of the present invention.
  • a pharmaceutically acceptable carrier with the compound of formula (I), stereoisomers, and tautomers described in the first aspect of the present invention.
  • Forms, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs are mixed to form a pharmaceutical composition.
  • the fourth aspect of the present invention provides the compound of formula (I) described in the first aspect, its stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug , Or the use of the pharmaceutical composition of the third aspect to prepare a pharmaceutical composition for preventing and/or treating diseases related to the activity or expression of KRAS G12C.
  • the fifth aspect of the present invention provides a method for preventing and/or treating diseases related to the activity or expression level of KRAS G12C , which comprises the step of: administering an effective amount of the compound of formula (I) described in the first aspect to the patient in need , Its stereoisomers, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or administration of the pharmaceutical composition described in the third aspect.
  • the disease is a tumor or a disordered disease.
  • the disease is selected from the following group: lung cancer, breast cancer, prostate cancer, esophageal cancer, colorectal cancer, bone cancer, kidney cancer, gastric cancer, liver cancer, colorectal cancer, melanoma, lymphoma, blood cancer , Brain tumor, myeloma, soft tissue sarcoma, pancreatic cancer, skin cancer.
  • the sixth aspect of the present invention provides a non-diagnostic and non-therapeutic method for inhibiting KRAS G12C , which comprises the steps of: administering to a patient in need an effective amount of the compound of formula (I) described in the first aspect, and its stereospecificity Constructs, tautomers, crystal forms, pharmaceutically acceptable salts, hydrates, solvates or prodrugs, or administration of the pharmaceutical composition described in the third aspect.
  • the seventh aspect of the present invention provides a method for inhibiting the inhibition of KRAS G12C in vitro, which comprises the steps of: combining the compound described in the first aspect, its stereoisomers, tautomers, crystal forms, and pharmaceutically acceptable salts , Hydrate, solvate or prodrug, or the composition of the third aspect, in contact with somatic cells.
  • the somatic cells are derived from primates (such as humans).
  • the inventors unexpectedly prepared a new type of KRAS G12C compound with selective inhibition and/or better pharmacodynamic properties. On this basis, the inventor completed the present invention.
  • substituent When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes the chemically equivalent substituent obtained when the structural formula is written from right to left.
  • substituent -CH 2 O- is equivalent to -OCH 2 -.
  • alkyl refers to a straight or branched chain alkane group, which can include any number of carbon atoms, where "C 1 -C 18 alkyl” refers to including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 carbon atoms, preferably, for example, C 1 -C 2 , C 1 -C 3 , C 1 -C 4 , C 1- C 5 , C 1 -C 6 , C 1 -C 7 , C 1 -C 8 , C 1 -C 9 , C 1 -C 10 , C 2 -C 3 , C 2 -C 4 , C 2 -C 5 , C 2 -C 6 , C 3 -C 4 , C 3 -C 5 , C 3 -C 6 , C 4 -C 5 , C 4 -C 6 or C 5-6 .
  • alkyl includes but is not limited to methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, isobutyl, Pentyl, isopentyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl etc.
  • the alkyl group also includes a substituted alkyl group. "Substituted alkyl” means that one or more positions in the alkyl group are substituted, especially 1-4 substituents, which can be substituted at any position.
  • cycloalkyl refers to a fully saturated cyclic hydrocarbon compound group, where "C 3 -C 20 cycloalkyl” refers to containing 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms fully saturated cyclic hydrocarbon compound group, including 1-4 rings, each ring contains 3-8 carbon atom. Preferably, it is C 3 -C 4 , C 3 -C 5 , C 3 -C 6 , C 3 -C 7 , C 3 -C 8 , C 3 -C 9 , C 3 -C 10 .
  • Substituted cycloalkyl means that one or more positions in the cycloalkyl group are substituted, especially 1-4 substituents, which can be substituted at any position.
  • cycloalkyl is intended to include “substituted cycloalkyl”.
  • heterocyclic group refers to a fully saturated or partially unsaturated cyclic group
  • heterocyclic group refers to a group containing 3, 4, 5, 6, 7, 8, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 ring atoms fully saturated or partially unsaturated cyclic groups (including but not limited to such as 3-7 membered monocyclic ring, 6 -11-membered bicyclic ring, or 8-16-membered tricyclic ring system), in which at least one heteroatom is present in a ring with at least one carbon atom.
  • Each heterocyclic ring containing heteroatoms can have 1, 2, 3, or 4 heteroatoms, and these heteroatoms are selected from nitrogen, oxygen or sulfur, wherein nitrogen or sulfur can be oxidized, and nitrogen can also be quaternized.
  • the heterocyclic group can be attached to any heteroatom or carbon atom residue of the ring or ring system molecule.
  • Typical monocyclic heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, oxetanyl, pyrazolinyl, imidazolinyl, imidazolidinyl, oxazolidinyl, isoxazole Alkyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, hexahydroacridine Heptinyl, 4-piperidinone, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinylsulfone, 1,3-dioxanyl And tetrahydro-1,1-dioxythiophene and so on
  • Polycyclic heterocyclic groups include spiro, condensed and bridged heterocyclic groups; the spiro, condensed and bridged heterocyclic groups involved are optionally connected to other groups through a single bond, or through a ring Any two or more of the above atoms are further connected to other cycloalkyl groups, heterocyclic groups, aryl groups and heteroaryl groups; the heterocyclic group may be substituted or unsubstituted.
  • aryl refers to an aromatic cyclic hydrocarbon compound group, where "C6-C14 aryl” refers to a group containing 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms
  • Aromatic cyclic hydrocarbon compound groups have 1-5 rings, especially monocyclic and bicyclic groups, such as phenyl, biphenyl or naphthyl. Where there are two or more aromatic rings (bicyclic, etc.), the aromatic ring of the aryl group can be connected by a single bond (such as biphenyl) or condensed (such as naphthalene, anthracene, etc.).
  • “Substituted aryl” means that one or more positions in the aryl group are substituted, especially 1-3 substituents, which can be substituted at any position.
  • heteroaryl refers to an aromatic cyclic hydrocarbon compound group containing 1 to 4 heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen and sulfur.
  • heteroatoms are selected from oxygen, nitrogen and sulfur.
  • heteroaryl refers to an aromatic cyclic hydrocarbon compound group containing 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 ring atoms, wherein the ring atoms Contain 1-4 heteroatoms selected from N, O, S.
  • Heteroaryl groups are preferably 5- to 10-membered rings, more preferably 5-membered or 6-membered.
  • Heteroaryl groups include but are not limited to pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadi Azolyl, isothiazolyl, furanyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl and tetrazolyl, etc.
  • alkoxy refers to a straight or branched chain or cyclic alkoxy group
  • C1-C18 alkoxy refers to a straight or branched chain or cyclic alkyl group having 1 to 18 carbon atoms
  • the oxy group includes C1-C18 alkyl-O-, -C1-C6 alkyl-O-C1-C6 alkyl, preferably C1-C8 alkoxy, more preferably C1-C6 alkoxy, alkoxy includes But it is not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy.
  • Cycloalkenyl refers to a cyclic hydrocarbon group with one or more double bonds, where "C 4 -C 10 cycloalkenyl” refers to one or more double bonds, including 4, 5, 6, 7, Cyclic hydrocarbon groups with 8, 9 or 10 carbon atoms, preferably C 4 -C 6 cycloalkenyl groups, including but not limited to: cyclobutenyl, cyclopentenyl, cyclopentadienyl, cycloalkenyl Hexenyl, cyclohexadienyl, etc.
  • ester group refers to a group with the structure -COOR, where R represents hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl Group or substituted aryl group, heteroaryl group or substituted heteroaryl group, heterocyclic group or substituted heterocyclic group.
  • R represents hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, aryl Group or substituted aryl group, heteroaryl group or substituted heteroaryl group, heterocyclic group or substituted heterocyclic group.
  • amino refers to a group with the structure -NRR', where R and R'can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or A substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclic or substituted heterocyclic group.
  • R and R' can be the same or different.
  • the amine group is -NH 2 .
  • amine groups include, but are not limited to, methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, butylamino, and the like.
  • amide group refers to a group with the structure -CONRR', where R and R'can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or A substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclic or substituted heterocyclic group.
  • R and R' can be the same or different.
  • sulfonamido refers to a group with the structure -SO 2 NRR', where R and R'can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, ring Alkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclic or substituted heterocyclic.
  • R and R' can be the same or different.
  • aminosulfonyl refers to a group with the structure -NRSO 2 R', where R and R'can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, Cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclic or substituted heterocyclic.
  • R and R' can be the same or different.
  • ureido refers to a group with the structure -NRCONR'R", where R, R'and R" can independently represent hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl , Cycloalkenyl or substituted cycloalkenyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, heterocyclic group or substituted heterocyclic group.
  • the alkyl group, cycloalkyl group, cycloalkenyl group, aryl group, heteroaryl group, and heterocyclic group have the definitions as described above.
  • R, R'and R" may be the same or different.
  • a substituent is a non-terminal substituent or a related group has one H atom removed, it is a subunit of the corresponding group, usually a divalent group, for example, an alkyl group has an alkylene group after one H atom removed (e.g. :Methylene, ethylene, propylene, isopropylidene (such as ), butylene (e.g. ), pentylene (e.g. ), hexyl (e.g. ), Heptyl (e.g.
  • the cycloalkyl group corresponds to the cycloalkylene group (such as: Etc.)
  • the heterocyclic group corresponds to the heterocyclylene group (such as: )
  • cycloalkyl corresponds to heterocyclylene (such as: Etc.)
  • alkoxy corresponds to alkyleneoxy (-CH 2 O-, -CH 2 CH 2 -O-CH 2 -, -CH 2 OCH 2 CH 2 CH 2 -) and so on.
  • halogen refers to chlorine, bromine, fluorine, and iodine.
  • halo means that the H in the group is replaced by halogen.
  • deuterated means that the H in the group is replaced by deuterium.
  • hydroxyl refers to a group with the structure OH.
  • nitro refers to a group bearing the structure NO 2.
  • cyano refers to a group bearing the structure CN.
  • substituted or unsubstituted groups means that the H atom of the selected group is substituted or unsubstituted, and the selected group does not contain a H atom and will not be substituted.
  • the compounds of the present invention can be combined with any number of substituents or functional groups to expand their scope of inclusion.
  • substituents or functional groups to expand their scope of inclusion.
  • the general formula including substituents in the formula of the present invention refers to the replacement of hydrogen radicals with designated structural substituents.
  • each position of the substituents may be the same or different.
  • substitution as used herein includes all permissible substitution of organic compounds. Broadly speaking, the permissible substituents include acyclic, cyclic, branched unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic organic compounds.
  • the heteroatom nitrogen may have hydrogen substituents or any permitted organic compounds described above to supplement its valence.
  • the present invention is not intended to limit the permitted substitution of organic compounds in any way.
  • the present invention believes that the combination of substituents and variable groups is good in the treatment of diseases in the form of stable compounds, such as infectious diseases or proliferative diseases.
  • stable here refers to a compound that is stable and can be tested for a long enough time to maintain the structural integrity of the compound, preferably for a long enough time to be effective, and is used herein for the above purpose.
  • substituted means that one or more hydrogen atoms on a specific group are replaced by a specific substituent.
  • the specific substituents are the substituents correspondingly described in the foregoing, or the substituents appearing in each embodiment.
  • a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituent may be the same or different in each position.
  • the groups include corresponding substituent groups and subgroups, for example, alkyl groups include substituted alkyl groups, cycloalkyl groups include substituted cycloalkyl groups, and aryl groups include substituted aryl groups.
  • Heteroaryl groups include substituted heteroaryl groups
  • heterocyclic groups include substituted heterocyclic groups and the like.
  • substituents contemplated by the present invention are those that are stable or chemically achievable.
  • alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocyclyl, heteroaryl or aryl and their corresponding substituents and subunits can be optionally substituted, wherein ,
  • the alkyl group, cycloalkyl group, cycloalkenyl group, heterocyclic group, heteroaryl group or aryl group has the above-mentioned definition.
  • the terms "compounds of the present invention” or “active ingredients of the present invention” are used interchangeably and refer to compounds of formula (I), or pharmaceutically acceptable salts, hydrates, solvates, isotopic compounds (such as Deuterated compounds) or prodrugs.
  • the term also includes racemates and optical isomers.
  • the compound of formula (I) has the following structure:
  • R 1 , R 2 , R 4 , L, U, V, W, Q, A, B, and X are as described above.
  • the compound of formula (I) has a structure represented by formula (II-A) or (II-B):
  • R 1 , R 2 , R 4 , A, B, L, X, U, V, W, and Q are as described above.
  • the compound of formula (I) has a structure represented by formula (III):
  • R 1 , R 2 , R 4 , X, L, U, V, W, and Q are as described above.
  • the compound of formula (I) has a structure represented by formula (IV):
  • R 1 , R 2 , R 4 , R 8 , L, U, V, W, and Q are as described above.
  • the compound of formula (I) has a structure represented by formula (V):
  • R 1 , R 2 , R 4 , R 8 , U, V, W, and Q are as described above.
  • the compound of formula (I) has a structure represented by formula (VI):
  • R 1 , R 2 , R 4 , R 8 , U, V, and Q are as described above.
  • the compound of formula (I) has a structure represented by formula (VII):
  • R 1 , R 2 , R 4 , R 8 , V, and Q are as described above.
  • R A is independently selected from the following group: hydrogen, deuterium, fluorine, cyano or C 1 -C 3 alkyl
  • each R B is the same or different, and is independently selected from the following group: hydrogen, deuterium, cyano or C 1 -C 3 alkyl; wherein, the alkyl can be substituted by one or more (such as 2, 3, 4 or 5) substituents selected from the following group: deuterium, halogen, cyano, amine, C 3 -C 7 cycloalkyl, 4-7 membered heterocyclic group, NHR 9 or NR 9 R 10 ; R 9 and R 10 are each independently a C 1 -C 3 alkyl group; or R 9 , R 10 are connected to it The N atoms of together form a substituted or unsubstituted 4-8 membered heterocyclic group;
  • R 6 is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 6 alkyl, deuterated C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, deuterated C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkoxy, 4-8 membered heterocyclic group, C 6 -C 14 aromatic Group, 5-14 membered heteroaryl group;
  • substitution refers to the substitution by one or more groups selected from the following group: hydrogen, deuterium, C 1 -C 6 alkyl, and deuterated C 1 -C 6 unless otherwise specified.
  • Q is N.
  • V and W are each independently CR 3 , and R 3 is H or halogen; preferably, R 3 is halogen.
  • R 8 is independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 6 alkyl, deuterated C 1 -C 6 alkyl, halo C 1 -C 6 alkyl , C 3 -C 8 cycloalkyl, C 1 -C 6 alkoxy, deuterated C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkoxy, amino, hydroxyl, 4-8 membered hetero Cyclic; the substitution refers to the substitution by one or more (such as 2, 3, 4 or 5) groups selected from the following group: hydrogen, deuterium, halogen, nitro, hydroxyl, cyano, ester, Amine group, amide group, sulfonamide group or ureido group; more preferably, R 8 is independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, C 1 -C 6 alkyl, deuterated C 1- C
  • each R 8 is a methyl group.
  • the compound has a structure represented by formula (VIII):
  • R"' are each independently selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl, wherein the substitution means selected Substituting one or more groups from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl group, 5-14 membered heteroaryl group;
  • q is selected from: 1, 2, 3, or 4;
  • R 1 , R 4 , R 8 , R', V, and Q are as described above.
  • the compound has a structure represented by formula (IX):
  • R 1 , R 4 , R', V, R"', Q and q are as described above.
  • Rx is selected from: hydrogen, deuterium, C 1 -C 3 alkyl, deuterated C 1 -C 3 alkyl, halogenated C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, C 1- C 3 alkoxy, halogen, nitro, hydroxyl, cyano, ester, 4-6 membered heterocyclic group, preferably, Partly
  • Rx is selected from: hydrogen, deuterium, C 1 -C 3 alkyl, deuterated C 1 -C 3 alkyl, halogenated C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl, C 1- C 3 alkoxy, halogen, nitro, hydroxyl, cyano, ester, 4-6 membered heterocyclic group, preferably, Partly
  • R 2 is selected from the following group:
  • K is independently O, S, CH2 or NH; e and f are each independently 0, 1 or 2, preferably H in the above groups can be optionally deuterated, halogen, nitro, hydroxyl, cyano, Ester group, amine group, amide group, C 1 -C 3 alkyl substitution.
  • the compound has a structure represented by formula (VIII):
  • R"' is selected from the following group of substituted or unsubstituted groups: hydrogen, deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl, wherein the substitution refers to being selected from the following group Substitution of one or more groups: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4- C 10 cycloalkenyl, 4-8 membered heterocyclic group, C 6 -C 14 aryl, 5-14 membered heteroaryl;
  • R 1 , R 4 , R 8 , R′, V, Q, and q are as described above.
  • R"' is selected from the following group of substituted or unsubstituted groups: C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 10 cycloalkenyl, 4-8 membered heterocycle Group, C 6 -C 10 aryl group, 5-10 membered heteroaryl group, wherein the substitution refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano , Ester group, amino group, amide group, C 1 -C 6 alkyl group, C 3 -C 8 cycloalkyl group, 4-8 membered heterocyclic group.
  • R"' is selected from the following group of substituted or unsubstituted groups: C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 4 -C 6 cycloalkenyl, 4-6 membered heterocycle More preferably, R"' is selected from the following substituted or unsubstituted groups: radical, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylamino, Azetidinyl, azetidinyl, azetidinyl, oxiranyl, oxetanyl, oxolanyl, oxetanyl, of which, The substitution refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3
  • Part of it is selected from the following group:
  • K is independently O, S, CH 2 or NH; e and f are each independently 0, 1 or 2, preferably H in the above groups can be optionally deuterated, halogen, nitro, hydroxyl, cyano , Ester group, amine group, amide group, C 1 -C 3 alkyl substitution.
  • the compound has a structure represented by formula (X) or (XI):
  • Rm is selected from the following group of substituted or unsubstituted groups: amino group, C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group, 4-6 membered heterocyclic group, wherein the substitution refers to the selected Substituting one or more groups from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl, C3-C6 cycloalkyl, 4- 6-membered heterocyclic group;
  • Rn is selected from the following group of substituted or unsubstituted groups: amino, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, -OC 3 -C 6 cycloalkane Group, C 1 -C 6 alkyl C 3 -C 6 cycloalkyl, -OC 1 -C 6 alkyl C 3 -C 6 cycloalkyl, 4-6 membered heterocyclic group, wherein the substitution refers to Substituted by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl, C 1 -C 3 haloalkyl , C3-C6 cycloalkyl, 4-6 membered heterocyclic group;
  • Rx is selected from: F or Cl
  • R A is selected from: H, D, halo, or cyano, preferably R A is selected from: H or F.
  • R"' is as described above;
  • q' is selected from 0, 1, 2, or 3.
  • the compound has a structure represented by formula (VIII-1):
  • R 1 , Rx, R 4 , Rm and Rn are as defined above.
  • the compound has a structure represented by formula (X)
  • R A , Rx, R 4 , Rm, Rn, q"' and q' are as defined above.
  • the compound has a structure represented by formula (XII)
  • R 4a, R 4b, R 4c, R 4d, R 4e, Rm, Rn, Rx, R A, q ', R "' described above.
  • the compound has a structure represented by formula (XIV):
  • Rn is selected from the following group of substituted or unsubstituted groups: ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylamino, azetidine Alkyl, azepanyl, azetidine, oxiranyl, oxetanyl, oxolane, oxetanyl, wherein the substitution is Refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • Rm is selected from the following group of substituted or unsubstituted groups: methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylamino, nitrogen Etanyl, azepanyl, azetidine, oxiranyl, oxetanyl, oxolanyl, oxetanyl, among which,
  • the substitution refers to substitution by one or more groups selected from the following group: deuterium, halogen, nitro, hydroxyl, cyano, ester, amine, amide, C 1 -C 3 alkyl.
  • Salts that may be formed by the compounds of the present invention also belong to the scope of the present invention. Unless otherwise specified, the compounds in the present invention are understood to include their salts.
  • the term "salt” as used herein refers to a salt formed into an acid or basic form with an inorganic or organic acid and a base.
  • the compound of the present invention contains a basic fragment, it includes but is not limited to pyridine or imidazole, and when it contains an acidic fragment, including but not limited to carboxylic acid, the zwitterion (“internal salt") that may be formed is contained in Within the scope of the term "salt”.
  • salts are preferred, although other salts are also useful, for example, they can be used in separation or purification steps in the preparation process.
  • the compound of the present invention may form a salt.
  • the compound I can be obtained by reacting with a certain amount of acid or base, such as an equivalent amount, to salt out in the medium, or freeze-dried in an aqueous solution.
  • the basic fragments contained in the compounds of the present invention may form salts with organic or inorganic acids.
  • Typical acids that can form salts include acetate (such as acetic acid or trihaloacetic acid, such as trifluoroacetic acid), adipate, alginate, ascorbate, aspartate, and benzoate.
  • Benzene sulfonate hydrogen sulfate, borate, butyrate, citrate, camphor salt, camphor sulfonate, cyclopentane propionate, diglycolate, dodecyl sulfate, Ethane sulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, caproate, hydrochloride, hydrobromide, hydroiodide, isethionate (E.g. 2-hydroxyethanesulfonate), lactate, maleate, methanesulfonate, naphthalenesulfonate (e.g.
  • 2-naphthalenesulfonate nicotinate, nitrate, oxalic acid Salt, pectinate, persulfate, phenylpropionate (such as 3-phenylpropionate), phosphate, picrate, pivalate, propionate, salicylate, succinate, Sulfate (such as formed with sulfuric acid), sulfonate, tartrate, thiocyanate, toluenesulfonate such as p-toluenesulfonate, dodecanoate, etc.
  • the acidic fragments that some compounds of the present invention may contain, including but not limited to carboxylic acids, may form salts with various organic or inorganic bases.
  • Typical salts formed by bases include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, and salts formed by organic bases (such as organic amines) such as benzathine and bicyclohexyl Amine, Hypamine (a salt formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucosamine, N-methyl-D-glucamide, tert-butyl Base amines, and salts with amino acids such as arginine, lysine, etc.
  • Basic nitrogen-containing groups can be combined with halide quaternary ammonium salts, such as small molecular alkyl halides (such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides), dialkyl sulfates (E.g., dimethyl sulfate, diethyl, dibutyl and dipentyl sulfate), long-chain halides (such as chlorides and bromides of decyl, dodecyl, tetradecyl and tetradecyl And iodides), aralkyl halides (such as benzyl and phenyl bromides) and so on.
  • small molecular alkyl halides such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides
  • dialkyl sulfates E.g., dimethyl sulfate, diethyl
  • prodrugs and solvates of the compounds of the present invention are also covered.
  • prodrug herein refers to a compound that undergoes metabolic or chemical transformation to produce the compound, salt, or solvate of the present invention when treating related diseases.
  • the compounds of the present invention include solvates, such as hydrates.
  • the compounds, salts or solvates of the present invention may exist in tautomeric forms (such as amides and imine ethers). All these tautomers are part of the invention.
  • All stereoisomers of compounds (for example, those asymmetric carbon atoms that may exist due to various substitutions), including their enantiomeric forms and diastereomeric forms, fall within the scope of the present invention.
  • the independent stereoisomers of the compound in the present invention may not coexist with other isomers (for example, as a pure or substantially pure optical isomer with special activity), or may be a mixture, such as Racemates, or mixtures with all other stereoisomers or part of them.
  • the chiral center of the present invention has two configurations, S or R, defined by the International Union of Theoretical and Applied Chemistry (IUPAC) in 1974.
  • racemic form can be resolved by physical methods, such as fractional crystallization, or separation of crystallization by derivatization into diastereomers, or separation by chiral column chromatography.
  • Individual optical isomers can be obtained from racemates by suitable methods, including but not limited to traditional methods, such as salt formation with an optically active acid and recrystallization.
  • the weight content of the compound obtained by successive preparation, separation and purification is equal to or greater than 90%, for example, equal to or greater than 95%, equal to or greater than 99% ("very pure" compound), as described in the text Listed.
  • very pure compounds of the invention are also part of the invention.
  • All configuration isomers of the compounds of the present invention are within the scope of coverage, whether in mixture, pure or very pure form.
  • the definition of the compound of the present invention includes two olefin isomers, cis (Z) and trans (E), as well as cis and trans isomers of carbocyclic and heterocyclic rings.
  • Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms.
  • the present invention covers all compounds, including their cis and trans isomers, R and S enantiomers, diastereomers, (D) isomers, (L) isomers, and exogenous Spin mixtures and other mixtures.
  • the asymmetric carbon atom may represent a substituent, such as an alkyl group. All isomers and their mixtures are included in the present invention.
  • the ratio of the mixture of isomers containing the isomers can be varied.
  • a mixture of only two isomers can have the following combinations: 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98: 2, 99:1, or 100:0, all ratios of isomers are within the scope of the present invention. Similar ratios, which are easily understood by those skilled in the art, and ratios that are mixtures of more complex isomers are also within the scope of the present invention.
  • the present invention also includes isotopically labeled compounds, which are equivalent to the original compounds disclosed herein. In practice, however, it usually occurs when one or more atoms are replaced by atoms whose atomic weight or mass number is different.
  • isotopes that can be classified as compounds of the present invention include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine isotopes, such as 2 H, 3 H, 13 C, 11 C, 14 C, 15 N, and 18 O, respectively. , 17 O, 31 P, 32 P, 35 S, 18 F and 36 Cl.
  • the compounds of the present invention or enantiomers, diastereomers, isomers, or pharmaceutically acceptable salts or solvates, which contain isotopes or other isotopic atoms of the above compounds are all within the scope of the present invention.
  • Certain isotope-labeled compounds in the present invention such as radioisotopes of 3 H and 14 C, are also among them, which are useful in tissue distribution experiments of drugs and substrates.
  • Isotopically-labeled compounds can be prepared by general methods, by replacing readily available isotope-labeled reagents with non-isotopic reagents, using the protocol disclosed in the examples.
  • a specific enantiomer of the compound of the present invention can be prepared by asymmetric synthesis, or derivatized with a chiral adjuvant, and the resulting diastereomeric mixture is separated, and then the chiral adjuvant is removed. Pure enantiomer.
  • a suitable optically active acid or base can be used to form a diastereomeric salt with it, and then through separation crystallization or chromatography, etc. After separation by conventional means, the pure enantiomers are obtained.
  • the preparation process of the compound of the present invention is as follows, wherein the raw materials and reagents used can be purchased through commercial channels or synthesized according to reported literature unless otherwise specified.
  • E is halogen, OH, OCOR 1 , OCO ( i Bu), etc.
  • E 1 is -BH 2 , -B(OH) 2 , -Sn(Bu) 3 , -ZnBr, etc.;
  • PG is an amino protecting group, and the protecting group is selected from the group consisting of Boc, Bn, Cbz or Fmoc;
  • Y and Z are leaving groups, and the leaving groups are selected from the group consisting of halogen or OTf;
  • the first base is selected from the group consisting of KHMDS, NaHMDS, LiHMDS, NaH, NaOMe, NaOEt or t BuONa;
  • the second base is selected from the group consisting of TEA, DIPEA, DMAP or N,N-dimethylaniline;
  • R 1 , R 2 , R 4 , L, A, B, X, U, V, W, and Q are as described above.
  • reaction solvent the reaction solvent, reaction catalyst, base used in the reaction, reaction temperature, reaction time, etc.
  • reaction solvent the reaction solvent, reaction catalyst, base used in the reaction, reaction temperature, reaction time, etc.
  • the pharmaceutical composition of the present invention is used to prevent and/or treat the following diseases: inflammation, cancer, cardiovascular disease, infection, immune disease, and metabolic disease.
  • the compound of formula (I) can be used in combination with other drugs known to treat or improve similar conditions.
  • the original drug administration mode and dosage can remain unchanged, while the compound of formula (I) is administered at the same time or subsequently.
  • a pharmaceutical composition containing one or more known drugs and the compound of formula (I) can be preferably used.
  • the combination of drugs also includes taking the compound of formula (I) and one or more other known drugs in overlapping time periods.
  • the dose of the compound of formula (I) or a known drug may be lower than the dose of the compound used alone.
  • Drugs or active ingredients that can be used in combination with the compound of formula (I) include but are not limited to: PD-1 inhibitors (such as nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR -120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT1306, AK105, LZM 009 or biological analogues of the above drugs, etc.), PD-L1 inhibitors (such as Duval Monoclonal antibody, atezolizumab, avelumab, CS1001, KN035, HLX20, SHR-1316, BGB-A333, JS003, CS1003, KL-A167, F520, GR1405, MSB2311 or the above drugs Biosimilar drugs, etc.), CD20 antibodies (e.g.
  • rituximab obin utuzumab, ofatumumab, veltuzumab, tositumomab, 131I-tositumomab, crizuzumab Anti-, 90Y- ibritumomab, 90In- ibritumomab, ibritumomab tiuxetan, etc.), CD47 antibodies (such as Hu5F9-G4, CC-90002, TTI-621, TTI-622, OSE-172, SRF-231, ALX-148, NI-1701, SHR-1603, IBI188, IMM01), ALK inhibitors (such as ceritinib, alectinib, brigatinib, loratinib, Ocatinib), PI3K inhibitors (such as Adelaris, Duvelisib, Dactolisib, Taselisib, Bimiralisib, Omi
  • the dosage form of the pharmaceutical composition of the present invention includes (but is not limited to): injection, tablet, capsule, aerosol, suppository, film, dripping pill, external liniment, controlled release or sustained release or nano preparation.
  • the pharmaceutical composition of the present invention contains a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier.
  • the "safe and effective amount” refers to: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
  • the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per agent, and more preferably, contains 10-1000 mg of the compound of the present invention per agent.
  • the "one dose" is a capsule or tablet.
  • “Pharmaceutically acceptable carrier” refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use, and must have sufficient purity and sufficiently low toxicity. "Compatibility” here means that the components in the composition can be blended with the compound of the present invention and between them without significantly reducing the efficacy of the compound.
  • pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, and solid lubricants (such as stearic acid).
  • Magnesium stearate calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
  • vegetable oils such as soybean oil, sesame oil, peanut oil, olive oil, etc.
  • polyols such as propylene glycol, glycerin, mannitol, sorbitol, etc.
  • emulsifiers such as emulsifiers
  • wetting agents such as sodium lauryl sulfate
  • administration method of the compound or pharmaceutical composition of the present invention is not particularly limited.
  • Representative administration methods include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration .
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with the following ingredients: (a) fillers or compatibilizers, for example, Starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) humectants, For example, glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) Absorption accelerators, for example, quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and g
  • Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared with coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the active compound or the release of the compound in such compositions may be released in a certain part of the digestive tract in a delayed manner. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microcapsules with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1 , 3-Butanediol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
  • composition may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents and perfumes.
  • the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • suspending agents for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
  • composition for parenteral injection may contain physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
  • the dosage forms of the compound of the present invention for topical administration include ointments, powders, patches, sprays and inhalants.
  • the active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • the treatment method of the present invention can be administered alone or in combination with other treatment means or therapeutic drugs.
  • a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment.
  • the dosage is usually 1 to 2000 mg, preferably 50 to 1000 mg.
  • the specific dosage should also consider factors such as the route of administration, the patient's health status, etc., which are all within the skill range of a skilled physician.
  • the present invention also provides a method for preparing a pharmaceutical composition, which comprises the steps of: combining a pharmaceutically acceptable carrier with the compound of formula (I) or its crystal form, pharmaceutically acceptable salt, hydrate or solvent of the present invention The compound is mixed to form a pharmaceutical composition.
  • the present invention also provides a method of treatment, which includes the steps of: administering the compound of formula (I), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, of the present invention to a subject in need of treatment, Or administer the pharmaceutical composition of the present invention for selectively inhibiting KRAS G12C .
  • the present invention has the following main advantages:
  • the compound has a very good selective inhibitory effect on KRAS G12C;
  • the compound has better pharmacodynamics, pharmacokinetic properties and lower toxic and side effects; among them, the experimental results show that the pharmacokinetic properties of the compound containing the phenylsulfone structure are better than other structures, For example, compounds with pyridine sulfone structure, compounds with dimethylpiperazine structure have better efficacy than monomethylpiperazine;
  • the structure of the compound of the present invention is determined by nuclear magnetic resonance (NMR) and liquid mass spectrometry (LC-MS).
  • the solvent for determination includes deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated acetone (CD 3 COCD 3 ), deuterated chloroform (CDCl 3 ) and deuterated methanol ( CD 3 OD), etc.
  • the internal standard uses tetramethylsilane (TMS), and the chemical shift is measured in units of parts per million (ppm).
  • LC-MS Liquid chromatography mass spectrometry
  • Waters SQD2 mass spectrometer The measurement of HPLC uses Agilent1100 high pressure chromatograph (Microsorb 5 micron C18 100 x 3.0mm chromatographic column).
  • the thin layer chromatography silica gel plate uses Qingdao GF254 silica gel plate, the TLC uses 0.15-0.20mm, and the preparative thin layer chromatography uses 0.4mm-0.5mm.
  • Column chromatography generally uses Qingdao silica gel 200-300 mesh silica gel as a carrier.
  • the starting materials in the examples of the present invention are all known and commercially available, or can be synthesized by using or according to literature reported in the field.
  • 2,6-Dichloro-5-fluoronicotinamide (873mg, 4.2mmol) was dissolved in 15ml of anhydrous tetrahydrofuran, and oxalyl chloride (3.6mL, 42.0mmol) in dichloromethane (4.5 mL) solution. After the addition is complete, the mixture is refluxed and stirred at 75°C for 2 hours, and then concentrated to dryness under reduced pressure. The residue was diluted with 15 ml of anhydrous tetrahydrofuran and cooled to zero degrees.
  • the 7-chloro-6-fluoro-1-(4-methyl-2-(methylsulfonyl)pyridin-3-yl)pyridine[2,3-d]pyrimidine-2,4(1H,3H)- The diketone (300mg, 0.8mmol) was suspended in 9ml of acetonitrile, and N,N-diisopropylethylamine (0.77mL, 4.7mmol) and phosphorus oxychloride (0.36mL, 3.9mmol) were added dropwise, and the reaction solution changed to clarify. The reaction solution was stirred at 80°C for 1 hour, and concentrated to dryness under reduced pressure.
  • the crude product was dissolved in 6 mL of dichloromethane, cooled to zero, and N,N-diisopropylethylamine (0.38mL, 2.3mmol) and acryloyl chloride (63mg, 0.7mmol) in dichloromethane (1mL) were added dropwise. ) Solution.
  • the reaction solution was stirred at zero for 30 minutes, quenched with 20 ml of saturated sodium bicarbonate, and extracted 3 times with 20 ml of dichloromethane.
  • Step 7 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4 -Methyl-2-(methylsulfo)pyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 5-1 two isomers, Example 5A and Example 5B, were obtained by chiral separation:
  • Example 5A LC-MS: m/z 610(M+H) + .
  • Example 5B LC-MS: m/z 610(M+H) + .
  • Example 6-1 obtained two isomers Example 5A and Example 5B through chiral separation:
  • Example 6A LC-MS: m/z 622(M+H) + .
  • Example 6B LC-MS: m/z 622(M+H) + .
  • Example 10-1 two isomers, Example 10A and Example 10B, were obtained by chiral separation:
  • Example 10A LC-MS: m/z 624(M+H) + .
  • Example 10B LC-MS: m/z 624(M+H) + .
  • Example 12 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(2-ethyl-6-(methylsulfonyl)phenyl )-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 16-1 two isomers, Example 16A and Example 16B, were obtained by chiral separation:
  • Example 16A LC-MS: m/z 625(M+H) + .
  • Example 16B LC-MS: m/z 625(M+H) + .
  • Example 18-1 obtained two isomers, Example 18A and Example 18B, through chiral separation:
  • Example 18A LC-MS: m/z 625(M+H) + .
  • 1 H NMR 400MHz, DMSO
  • Example 18B LC-MS: m/z 625(M+H) + .
  • 1 H NMR 400MHz, DMSO
  • Example 20-1 obtained two isomers Example 20A and Example 20B through chiral separation:
  • Example 20A LC-MS: m/z 625(M+H) + .
  • Example 20B LC-MS: m/z 625(M+H) + .
  • Example 25-1 obtained two isomers Example 25A and Example 25B through chiral separation:
  • Example 25A LC-MS: m/z 636(M+H) + .
  • Example 25B LC-MS: m/z 636(M+H) + .
  • 1 H NMR 400MHz, DMSO
  • Example 29-1 obtained two isomers, Example 29A and Example 29B through chiral separation:
  • Example 29A LC-MS: m/z 625(M+H) + .
  • Example 29B LC-MS: m/z 625(M+H) + .
  • Example 30-1 obtained two isomers Example 30A and Example 30B through chiral separation:
  • Example 30A LC-MS: m/z 624(M+H) + .
  • 1 H NMR 400MHz, DMSO
  • 7.86 m, 2H
  • 7.47 m, 3H
  • 6.92–6.74 m,1H
  • 6.22(d,J 16.6Hz,1H)
  • 5.77(d,J 10.7Hz,1H)
  • Example 30B LC-MS: m/z 624(M+H) + .
  • Example 31-1 obtained two isomers, Example 31A and Example 31B through chiral separation:
  • Example 31A LC-MS: m/z 666(M+H) + .
  • 1 H NMR 400MHz, DMSO
  • 7.66(t,J 7.8Hz,1H)
  • 7.25(t,J 8.7Hz,1H)
  • 7.12(d,J 7.8Hz,1H)
  • 6.22(d,J 16.7Hz,1H)
  • 5.78(d,J 10.6Hz,1H)
  • 4.93(brs,1H) 4.35(m,2H), 4.10(m,1H ), 3.86–3.46(m,2H), 3.24(m,1H), 2.99(m,3H), 2.60(
  • Example 31B LC-MS: m/z 666(M+H) + .
  • Example 32-1 two isomers, Example 32A and Example 32B, were obtained by chiral separation:
  • Example 32A LC-MS: m/z 642(M+H) + .
  • Example 32B LC-MS: m/z 642(M+H) + .
  • Example 33-1 two isomers, Example 33A and Example 33B, were obtained by chiral separation:
  • Example 33A LC-MS: m/z 625(M+H) + .
  • Example 33B LC-MS: m/z 625(M+H) + .
  • Example 34-1 obtained two isomers, Example 34A and Example 34B, through chiral separation:
  • Example 34A LC-MS: m/z 643(M+H) + .
  • Example 34B LC-MS: m/z 643(M+H) + .
  • Example 35-1 two isomers, Example 35A and Example 35B, were obtained by chiral separation:
  • Example 35A LC-MS: m/z 636(M+H) + .
  • Example 35B LC-MS: m/z 636(M+H) + .
  • Example 36-1 obtained two isomers, Example 36A and Example 36B, through chiral separation:
  • Example 36A LC-MS: m/z 654(M+H) + .
  • Example 36B LC-MS: m/z 654(M+H) + .
  • Example 37-1 two isomers, Example 37A and Example 37B, were obtained by chiral separation:
  • Example 37A LC-MS: m/z 625(M+H) + .
  • Example 37B LC-MS: m/z 625(M+H) + .
  • Example 38-1 obtained two isomers, Example 38A and Example 38B, through chiral separation:
  • Example 38A LC-MS: m/z 625(M+H) + .
  • Example 38B LC-MS: m/z 625(M+H) + .
  • Example 39-1 obtained two isomers, Example 39A and Example 39B through chiral separation:
  • Example 39A LC-MS: m/z 625(M+H) + .
  • Example 39B LC-MS: m/z 625(M+H) + .
  • Example 40-1 obtained two isomers, Example 39A and Example 39B through chiral separation:
  • Example 40A LC-MS: m/z 625(M+H) + .
  • Example 40B LC-MS: m/z 625(M+H) + .
  • Example 41-1 two isomers, Example 41A and Example 41B, were obtained by chiral separation:
  • Example 41A LC-MS: m/z 606(M+H) + .
  • Example 41B LC-MS: m/z 606(M+H) + .
  • Example 42-1 obtained two isomers, Example 42A and Example 42B through chiral separation:
  • Example 42A LC-MS: m/z 606(M+H) + .
  • Example 42B LC-MS: m/z 606(M+H) + .
  • Example 43-1 obtained two isomers, Example 43A and Example 43B through chiral separation:
  • Example 43A LC-MS: m/z 606(M+H) + .
  • Example 43B LC-MS: m/z 606(M+H) + .
  • Example 44-1 obtained two isomers, Example 44A and Example 44B, through chiral separation:
  • Example 44A LC-MS: m/z 606(M+H) + .
  • Example 44B LC-MS: m/z 606(M+H) + .
  • Example 45-1 obtained two isomers, Example 45A and Example 45B through chiral separation:
  • Example 45A LC-MS: m/z 680(M+H) + .
  • Example 45B LC-MS: m/z 680(M+H) + .
  • Example 46-1 obtained two isomers, Example 46A and Example 46B, through chiral separation:
  • Example 46A LC-MS: m/z 694 (M+H) + .
  • Example 46B LC-MS: m/z 694(M+H) + .
  • Example 47-1 obtained two isomers, Example 47A and Example 47B, through chiral separation:
  • Example 47A LC-MS: m/z 681(M+H) + .
  • Example 47B LC-MS: m/z 681(M+H) + .
  • Example 48 (2-(4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-1-(2-isopropyl-6-(methylsulfone) )Phenyl)-2-oxo-1,2-dihydropyridine[2,3-d]pyrimidin-7-yl)-3-fluorophenyl)methyl carbamate
  • Example 48-1 obtained two isomers, Example 48A and Example 48B, through chiral separation:
  • Example 48A LC-MS: m/z 681(M+H) + .
  • Example 48B LC-MS: m/z 681(M+H) + .
  • Example 49-1 obtained two isomers, Example 49A and Example 49B, through chiral separation:
  • Example 49A LC-MS: m/z 680(M+H) + .
  • Example 49B LC-MS: m/z 680(M+H) + .
  • Example 50-1 obtained two isomers, Example 50A and Example 50B, through chiral separation:
  • Example 50A LC-MS: m/z 701(M+H) + .
  • Example 50B LC-MS: m/z 701(M+H) + .
  • 2,6-Dichloro-5-fluoronicotinamide (420mg, 2.0mmol) was dissolved in anhydrous tetrahydrofuran (7mL), and oxalyl chloride (1.7mL, 20.0mmol) in dichloromethane ( 2mL) solution. After the addition was completed, the mixture was refluxed and stirred at 75°C for 2 h, and then concentrated to dryness under reduced pressure. The residue was diluted with anhydrous tetrahydrofuran (7 mL) and cooled to 0°C. 2-(Methylsulfonyl)aniline (360mg, 2.1mmol) was dissolved in dry tetrahydrofuran (3mL), and then added dropwise to the above solution.
  • Step 5 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2 -(Methylsulfonyl)phenyl)pyridine[2,3-d]pyrimidin-2(1H)-one
  • Example 53-1 obtained two isomers Example 53A and Example 53B through chiral separation:
  • Example 53A LC-MS: m/z 596 (M+H) + .
  • Example 53B LC-MS: m/z 596(M+H) + .
  • Example 62-1 obtained two isomers, Example 62A and Example 62B, through chiral separation:
  • Example 62A LC-MS: m/z 692(M+H) + .
  • Example 62B LC-MS: m/z 692(M+H) + .
  • reaction solution was quenched with 30 mL of 1M phosphoric acid, and extracted twice with ethyl acetate.
  • 2,6-Dichloro-5-fluoronicotinic acid amide (7.7g, 37mmol) was dissolved in 100ml of anhydrous tetrahydrofuran, and oxalyl chloride (47g, 370mmol) was slowly added dropwise to this solution. After the addition is complete, the mixture is refluxed and stirred at 75°C for 2 hours, and then concentrated to dryness under reduced pressure. The residue was diluted with 100 ml of anhydrous tetrahydrofuran and cooled to zero degrees.
  • 2-Cyclobutyl-6-(methylsulfonyl)aniline (8.8g, 39mmol) was dissolved in 50ml of anhydrous tetrahydrofuran, and then added dropwise to the above solution.
  • the reaction solution was stirred at zero for 2 hours, quenched with saturated ammonium chloride/saturated brine (1:1, 100 mL), and then extracted twice with ethyl acetate (50 mL).
  • the organic phases were combined and dried, concentrated, and the residual solid was slurried with petroleum ether/ethyl acetate (5:1, 200 mL), filtered with suction, and dried to obtain the target product (12.7 g, yield: 75%).
  • the 7-chloro-1-(2-cyclobutyl-6-(methylsulfonyl)phenyl)-6-fluoropyrido[2,3-d]pyrimidine-2,4(1H,3H)-di The ketone (23.2g, 54.7mmol) was suspended in 350ml of acetonitrile, and N,N-diisopropylethylamine (42.3g, 328mmol) and phosphorus oxychloride (33.5g, 219mmol) were added dropwise, and the reaction solution became clear. The reaction solution was stirred at 80°C for 1 hour, and concentrated to dryness under reduced pressure.
  • Step 7 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(2-cyclobutyl-6-(methylsulfonyl) (Phenyl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 63-1 obtained two isomers, Examples 63A and 63B, through chiral separation:
  • Example 76 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-7-(1,4-dimethyl-1H-imidazol-5-yl)-6-fluoro -1-(2-isopropyl-6-(methylsulfonyl)phenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 78 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(2-isopropyl-6-(methylsulfonyl)benzene Yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 78-1 obtained two isomers, Example 78A and 78B, through chiral separation:
  • Example 79-1 obtained two isomers, Example 79A and 79B, through chiral separation:
  • Example 80 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2- Isopropyl-6-(isopropylsulfonyl)phenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 80-1 two isomers, Example 80A and 80B, were obtained by chiral separation:
  • Example 81 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(2-cyclopropyl-6-(methylsulfonyl)benzene Yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 81-1 obtained two isomers, Examples 81A and 81B through chiral separation:
  • Example 82 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-1-(2-ethyl-6-(isopropylsulfonyl)benzene Yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 82-1 two isomers, Example 82A and 82B, were obtained by chiral separation:
  • Example 83-1 two isomers, Example 83A and 83B, were obtained by chiral separation:
  • Example 84 4-((2S,5R)-4-acryloyl-2,5-dimethylpiperazin-1-yl)-6-chloro-1-(2-ethyl-6-(methylsulfon) Acyl)phenyl)-7-(2-fluoro-6-hydroxyphenyl)pyrido[2,3-d]pyrimidin-2(1H)-one
  • Example 84-1 two isomers, Example 84A and 84B, were obtained by chiral separation:
  • 2,6-Dichloro-5-fluoronicotinamide (420mg, 2.0mmol) was dissolved in anhydrous tetrahydrofuran (7mL), and oxalyl chloride (1.7mL, 20.0mmol) in dichloromethane ( 2mL) solution. After the addition was completed, the mixture was refluxed and stirred at 75°C for 2 h, and then concentrated to dryness under reduced pressure. The residue was diluted with anhydrous tetrahydrofuran (7 mL) and cooled to 0°C. 2-(Methylsulfonyl)aniline (360mg, 2.1mmol) was dissolved in dry tetrahydrofuran (3mL), and then added dropwise to the above solution.
  • Step 5 4-((S)-4-acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2 -(Methylsulfonyl)phenyl)pyridine[2,3-d]pyrimidin-2(1H)-one
  • Example 87-1 obtained two isomers, Example 87A and Example 87B through chiral separation:
  • Example 87A LC-MS: m/z 596 (M+H) + .
  • Example 87B LC-MS: m/z 596 (M+H) + .
  • the compounds to be tested are diluted in a gradient, each compound is diluted in 10 concentration gradients (diluted from 50 ⁇ M to 0.003 ⁇ M) and 100 nL is added to the corresponding wells of the microplate. After adding the drug, add 40 ⁇ L of phosphate buffer to each well in rows A, P and columns 1, 24, and then place the microtiter plate in a carbon dioxide incubator for 5 days.
  • Table 1 shows the anti-proliferative activity of the compound of the examples of the present invention on NCI-H358 (KRAS G12C mutation) cells.
  • Example 5 IC 50 NCI-H358( ⁇ M) Example 1 0.09 Example 2 0.54 Example 3 0.87 Example 4 0.42 Example 5 0.028 Example 5A 0.23 Example 5B 0.011 Example 6 0.028 Example 6A 0.2 Example 6B 0.015 Example 7 0.24 Example 8 0.17 Example 9 0.23 Example 10 0.010 Example 10A 0.28 Example 10B 0.005 Example 11 0.18 Example 12 0.041 Example 13 0.015 Example 14 0.36
  • Example 15 0.058 Example 16 0.012 Example 16A 0.72 Example 16B 0.007 Example 17 0.031 Example 18 0.030 Example 18A 0.013 Example 18B 0.46 Example 19 0.048 Example 20 0.023 Example 20A 1.5 Example 20B 0.013 Example 21 1.2 Example 22 0.039 Example 23 1.1 Example 24 0.028 Example 25 0.009 Example 25A 0.35 Example 25B 0.006 Example 26 0.018 Example 27 0.03 Example 28 0.026 Example 29 0.053 Example 30 0.018 Example 30A 0.74 Example 30B 0.011 Example 31 0.008 Example 31A 0.30 Example 31B 0.006 Example 53B 0.066 Example 54 2.5 Example 55 5.3 Example 56 8.0 Example 57 10
  • Example 58 10 Example 59 0.20 Example 60 >10 Example 61 >10 Example 63A 0.37 Example 63B 0.008 Example 64 0.12 Example 65 >10 Example 66 >10 Example 67 >10 Example 68 2.2 Example 69 >10 Example 70 >10 Example 71 >10 Example 72 >10 Example 73 >10 Example 74 >10 Example 75 >10 Example 76 >10 Example 77 >10 Example 78A 0.17 Example 78B 0.007 Example 79A 0.048 Example 79B 0.002 Example 80B 0.007 Example 81B 0.009 Example 82B 0.050 Example 83B 0.026 Example 84B 0.006 Example 85 0.62 Example 86 0.56 Example 87 0.037 Example 87A 0.029 Example 87B 0.43
  • Example 88 2.5
  • Example 89 5.3 Example 90
  • Example 91 1.5
  • Example 92 >10
  • the compounds of the examples of the present invention show good cell anti-proliferation activity on KRAS G12C mutant NCI-H358 cells.
  • R 4 is a substituted phenyl group
  • the activity is better than that of heteroaryl groups, especially compounds containing a phenylsulfone structure.
  • mice Male ICR mice weighing about 20-30 g, fasted overnight, were given 30 mg/kg of the solution of the compound of the present invention in Examples 10B, 16B, 18A, 63B, 78B [CMC/TW80 as carrier]. Blood was collected 0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 12 and 24 hours after administration of the compound of the present invention, and the concentration of the compound of the present invention in plasma was determined by LC/MS/MS.
  • test results show that the compound of the present invention has good pharmacokinetic properties relative to AMG510.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation. Le composé a une structure représentée par la formule (I). L'invention concerne également un procédé de préparation du composé et son utilisation en tant qu'inhibiteur de KRAS G12C. Le composé présente un excellent effet inhibiteur sélectif sur KRAS G12C, une pharmacodynamique et des propriétés pharmacocinétiques améliorées, ainsi que de très faibles effets secondaires toxiques.
PCT/CN2021/099875 2020-06-12 2021-06-11 Dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation Ceased WO2021249563A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/141360 WO2022135591A1 (fr) 2020-12-25 2021-12-24 Dérivé de pyridone ou de pyrimidone arylique ou hétéroarylique, et son procédé de préparation ainsi que son application

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010534664.1A CN113801113A (zh) 2020-06-12 2020-06-12 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN202010534664.1 2020-06-12
CN202011563650.9 2020-12-25
CN202011563650.9A CN114671866A (zh) 2020-12-25 2020-12-25 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2021249563A1 true WO2021249563A1 (fr) 2021-12-16

Family

ID=78846896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/099875 Ceased WO2021249563A1 (fr) 2020-06-12 2021-06-11 Dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation

Country Status (1)

Country Link
WO (1) WO2021249563A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
CN115175908A (zh) * 2020-01-13 2022-10-11 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2022266206A1 (fr) 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP4194452A4 (fr) * 2020-08-02 2024-08-21 Shanghai Zheye Biotechnology Co., Ltd. Composé aromatique et son application dans un médicament antitumoral
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
US12281113B2 (en) 2020-09-11 2025-04-22 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
US12421253B2 (en) 2020-12-16 2025-09-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
US12485122B2 (en) 2018-09-10 2025-12-02 Mirati Therapeutics, Inc. Combination of palbociclib and adagrasib for lung cancer

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201906821A (zh) * 2017-05-22 2019-02-16 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑及其使用方法
TW201922739A (zh) * 2017-09-08 2019-06-16 美商安進公司 Kras g12c抑制劑以及其使用方法
CN110366550A (zh) * 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
WO2019213516A1 (fr) * 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
US20190374542A1 (en) * 2018-06-12 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019241157A1 (fr) * 2018-06-11 2019-12-19 Amgen Inc. Inhibiteurs de kras g12c pour le traitement du cancer
WO2020106647A2 (fr) * 2018-11-19 2020-05-28 Amgen Inc. Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CN111205286A (zh) * 2020-01-13 2020-05-29 李丹 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用
CN111377918A (zh) * 2019-11-29 2020-07-07 苏州信诺维医药科技有限公司 一种kras抑制剂化合物
CN111484477A (zh) * 2019-01-29 2020-08-04 博瑞生物医药（苏州）股份有限公司 一种苯并吡啶酮杂环化合物及其用途
WO2020236948A1 (fr) * 2019-05-21 2020-11-26 Amgen Inc. Formes à l'état solide
WO2020239077A1 (fr) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application
CN112159405A (zh) * 2020-02-04 2021-01-01 广州必贝特医药技术有限公司 吡啶并嘧啶酮类化合物及其应用
CN112225734A (zh) * 2019-10-25 2021-01-15 南京瑞捷医药科技有限公司 Kras g12c抑制剂及其用途
WO2021011417A1 (fr) * 2019-07-12 2021-01-21 The Regents Of The University Of California Mise en contact avec la cible d'un anticorps monoclonal chimiquement régulé
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN112390796A (zh) * 2019-08-19 2021-02-23 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
CN112552294A (zh) * 2019-09-10 2021-03-26 上海翰森生物医药科技有限公司 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
CN112585129A (zh) * 2019-05-21 2021-03-30 益方生物科技(上海)股份有限公司 杂环化合物，其制备方法和用途
CN112574199A (zh) * 2020-05-20 2021-03-30 首药控股(北京)股份有限公司 Kras-G12C抑制剂杂环化合物
WO2021076655A1 (fr) * 2019-10-15 2021-04-22 Amgen Inc. Multithérapie d'inhibiteur de kras et d'inhibiteur de shp2 pour le traitement de cancers
WO2021081212A1 (fr) * 2019-10-24 2021-04-29 Amgen Inc. Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
CN112920183A (zh) * 2019-12-06 2021-06-08 南京圣和药业股份有限公司 作为kras-g12c抑制剂的化合物及其应用
WO2021113595A1 (fr) * 2019-12-06 2021-06-10 Beta Pharma, Inc. Dérivés de phosphore utilisés comme inhibiteurs de kras
WO2021121330A1 (fr) * 2019-12-18 2021-06-24 InventisBio Co., Ltd. Composés hétérocycliques, leurs procédés de préparation et leurs utilisations
WO2021121367A1 (fr) * 2019-12-19 2021-06-24 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de protéine mutante kras
WO2021126816A1 (fr) * 2019-12-16 2021-06-24 Amgen Inc. Schéma posologique d'un inhibiteur du kras g12c
CN113061132A (zh) * 2020-01-01 2021-07-02 上海凌达生物医药有限公司 一类稠环内酰胺类化合物、制备方法和用途
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113286794A (zh) * 2019-11-04 2021-08-20 北京加科思新药研发有限公司 Kras突变蛋白抑制剂

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110366550A (zh) * 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
TW201906821A (zh) * 2017-05-22 2019-02-16 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑及其使用方法
TW201922739A (zh) * 2017-09-08 2019-06-16 美商安進公司 Kras g12c抑制劑以及其使用方法
WO2019213516A1 (fr) * 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019241157A1 (fr) * 2018-06-11 2019-12-19 Amgen Inc. Inhibiteurs de kras g12c pour le traitement du cancer
US20190374542A1 (en) * 2018-06-12 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020106647A2 (fr) * 2018-11-19 2020-05-28 Amgen Inc. Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CN111484477A (zh) * 2019-01-29 2020-08-04 博瑞生物医药（苏州）股份有限公司 一种苯并吡啶酮杂环化合物及其用途
CN112585129A (zh) * 2019-05-21 2021-03-30 益方生物科技(上海)股份有限公司 杂环化合物，其制备方法和用途
WO2020236948A1 (fr) * 2019-05-21 2020-11-26 Amgen Inc. Formes à l'état solide
WO2020239077A1 (fr) * 2019-05-29 2020-12-03 上海翰森生物医药科技有限公司 Régulateur dérivé hétérocyclique contenant de l'azote, son procédé de préparation et son application
WO2021011417A1 (fr) * 2019-07-12 2021-01-21 The Regents Of The University Of California Mise en contact avec la cible d'un anticorps monoclonal chimiquement régulé
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途
CN112390796A (zh) * 2019-08-19 2021-02-23 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
CN112552294A (zh) * 2019-09-10 2021-03-26 上海翰森生物医药科技有限公司 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
WO2021076655A1 (fr) * 2019-10-15 2021-04-22 Amgen Inc. Multithérapie d'inhibiteur de kras et d'inhibiteur de shp2 pour le traitement de cancers
WO2021081212A1 (fr) * 2019-10-24 2021-04-29 Amgen Inc. Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
CN112225734A (zh) * 2019-10-25 2021-01-15 南京瑞捷医药科技有限公司 Kras g12c抑制剂及其用途
CN113286794A (zh) * 2019-11-04 2021-08-20 北京加科思新药研发有限公司 Kras突变蛋白抑制剂
CN111377918A (zh) * 2019-11-29 2020-07-07 苏州信诺维医药科技有限公司 一种kras抑制剂化合物
WO2021113595A1 (fr) * 2019-12-06 2021-06-10 Beta Pharma, Inc. Dérivés de phosphore utilisés comme inhibiteurs de kras
CN112920183A (zh) * 2019-12-06 2021-06-08 南京圣和药业股份有限公司 作为kras-g12c抑制剂的化合物及其应用
WO2021126816A1 (fr) * 2019-12-16 2021-06-24 Amgen Inc. Schéma posologique d'un inhibiteur du kras g12c
WO2021121330A1 (fr) * 2019-12-18 2021-06-24 InventisBio Co., Ltd. Composés hétérocycliques, leurs procédés de préparation et leurs utilisations
WO2021120045A1 (fr) * 2019-12-18 2021-06-24 InventisBio Co., Ltd. Composés hétérocycliques, leurs procédés de préparation et utilisations associées
WO2021121367A1 (fr) * 2019-12-19 2021-06-24 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de protéine mutante kras
CN113061132A (zh) * 2020-01-01 2021-07-02 上海凌达生物医药有限公司 一类稠环内酰胺类化合物、制备方法和用途
CN111205286A (zh) * 2020-01-13 2020-05-29 李丹 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN112159405A (zh) * 2020-02-04 2021-01-01 广州必贝特医药技术有限公司 吡啶并嘧啶酮类化合物及其应用
CN112574199A (zh) * 2020-05-20 2021-03-30 首药控股(北京)股份有限公司 Kras-G12C抑制剂杂环化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRIAN A LANMAN; JENNIFER R ALLEN; JOHN G ALLEN; ALBERT K AMEGADZIE; KATE S ASHTON; SHON K BOOKER; JIAN JEFFREY CHEN; NING CHEN; MI: "Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 1, 9 January 2019 (2019-01-09), pages 52 - 65, XP055666907, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01180 *
CHEN HAO, SMAILL JEFF B., LIU TONGZHENG, DING KE, LU XIAOYUN: "Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 23, 23 November 2020 (2020-11-23), US, pages 14404 - 14424, XP055879585, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c01312 *
XIAO XUANZHENG; LAI MENGZHEN; SONG ZILAN; GENG MEIYU; DING JIAN; XIE HUA; ZHANG AO: "Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 213, 4 December 2020 (2020-12-04), pages 1 - 17, XP086503244, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.113082 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
US12485122B2 (en) 2018-09-10 2025-12-02 Mirati Therapeutics, Inc. Combination of palbociclib and adagrasib for lung cancer
US12336995B2 (en) 2018-09-10 2025-06-24 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
US11548888B2 (en) 2019-01-10 2023-01-10 Mirati Therapeutics, Inc. KRas G12C inhibitors
US11964989B2 (en) 2019-08-29 2024-04-23 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
US12304915B2 (en) 2019-12-20 2025-05-20 Mirati Therapeutics, Inc. SOS1 inhibitors
US11702418B2 (en) 2019-12-20 2023-07-18 Mirati Therapeutics, Inc. SOS1 inhibitors
CN115175908B (zh) * 2020-01-13 2024-07-23 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115175908A (zh) * 2020-01-13 2022-10-11 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
EP4194452A4 (fr) * 2020-08-02 2024-08-21 Shanghai Zheye Biotechnology Co., Ltd. Composé aromatique et son application dans un médicament antitumoral
US12286431B2 (en) 2020-09-11 2025-04-29 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12281113B2 (en) 2020-09-11 2025-04-22 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
US12421253B2 (en) 2020-12-16 2025-09-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-KRas inhibitors
WO2022266206A1 (fr) 2021-06-16 2022-12-22 Erasca, Inc. Conjugués d'inhibiteurs de kras

Similar Documents

Publication Publication Date Title
WO2021143693A1 (fr) Dérivé de pyridone ou de pyrimidine aryle ou hétéroaryle, son procédé de préparation et son utilisation
WO2021249563A1 (fr) Dérivé de pyridone ou de pyrimidone aryle ou hétéroaryle, son procédé de préparation et son utilisation
JP7462985B2 (ja) 芳香族化合物および抗腫瘍薬物の調製におけるその使用
WO2021228161A1 (fr) Inhibiteur hétérocyclique substitué par alkyle, son procédé de préparation et son utilisation
WO2021078312A1 (fr) Inhibiteurs de cycloalkyles et d'hétéro-cycloalkyles, leurs procédés de préparation et leur utilisation
KR20220119088A (ko) Kras 돌연변이체 단백질 억제제
WO2022199586A1 (fr) Inhibiteur de pyrimidopyridine, son procédé de préparation et son utilisation
WO2021088938A1 (fr) Inhibiteur à base de tétrahydropyridopyrimidine, son procédé de préparation et son utilisation
WO2022161480A1 (fr) Inhibiteur amine hétérocyclique bicyclo-aromatique substitué, son procédé de préparation et son utilisation
CN113105448A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
ES2927529T3 (es) Compuesto heterocíclico condensado
WO2022166592A1 (fr) Inhibiteur de pyrimidopyridone substitué, son procédé de préparation et son utilisation
EP4234548A1 (fr) Inhibiteur d'amine benzo ou pyridopyrimidine substitué, son procédé de préparation et son application
CN119060066A (zh) 取代的芳基或杂芳基并双环类抑制剂及其制备方法和应用
WO2025149082A1 (fr) Inhibiteur de cycle de pont substitué, son procédé de préparation et son utilisation
CN113801113A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115215869A (zh) 取代三环类抑制剂及其制备方法和应用
CN119019382A (zh) 取代的芳基或杂芳基并杂环烷基类抑制剂及其制备方法和应用
WO2023078451A1 (fr) Composé utile en tant qu'inhibiteur de kinase cdk7 et son utilisation
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
WO2022135591A1 (fr) Dérivé de pyridone ou de pyrimidone arylique ou hétéroarylique, et son procédé de préparation ainsi que son application
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
CN115215844A (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
WO2022143695A1 (fr) Inhibiteur de sulfonamide, son procédé de préparation et son utilisation
CN114380805A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21822964

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21822964

Country of ref document: EP

Kind code of ref document: A1